Carbonic anhydrase (CA) enzymes, specifically membrane-bound isozymes CA IX and CA XII, underpin a pH-regulating system that enables hypoxic tumor cell survival and proliferation. CA IX and XII are implicated as potential targets for the development of new hypoxic cancer therapies. To date only a few small molecules have been characterized in CArelevant cell and animal model systems. In this paper we describe the development of a new class of carbohydrate-based small molecule CA inhibitors, many of which inhibit CA IX and XII within a narrow range of low nanomolar K i values (5.3-11.2 nM). We evaluate for the first time carbohydrate-based CA inhibitors in cell-based models that emulate the protective role of CA IX in an acidic tumor microenvironment. Our findings identified two inhibitors (compounds 5 and 17) that block CA IX-induced survival and have potential for development as in vivo cancer-cell selective inhibitors.
Background
Tumor cells alter their metabolism when in a low oxygen (hypoxic) microenvironment to survive, proliferate and metastasise. 1 The hypoxia-inducible transcription factor regulates gene expression of proteins that are responsible for alterations in hypoxic tumor cell metabolism -one core aspect of which is the shift from aerobic to fermentative glycolysis. 2 Fermentative glycolysis leads to elevated lactic acid production, hence a drop in the intracellular pH (pH i ) of hypoxic tumor cells is expected unless pH homeostasis is established. 3 Carbonic anhydrase (CA, EC 4.2.1.1) enzymes, specifically isozymes CA IX and CA XII, have been shown to underpin a robust pH-regulating system by maintaining a pH i range compatible with cell viability and proliferation, while they contribute to the extracellular acidification of the tumor microenvironment. These enzymes confer a survival advantage to tumor cells growing in a hypoxic and acidic microenvironment. 4 CAs catalyze the reversible hydration of carbon dioxide (CO 2 ) to generate a bicarbonate anion (HCO 3 -) and a proton (H + ). 5 CA IX and XII differ from cytosolic CAs in that they are transmembrane proteins with an extracellular catalytic domain. 5 A characterized role of CA IX and XII in cancer is the hydration of tumor cell generated CO 2 , the net effect is to trap H + extracellularly, lowering pH outside the cell (pH o ) whilst maintaining normal pH i . 3, 6 CA IX and XII expression is upregulated in a wide variety of human tumors under the control of HIF-1, CA IX is commonly absent in corresponding normal tissue (except the stomach and GI tract), while CA XII is expressed in a selection of normal tissues. 7 The impact of modulating CA activity on tumor growth was recently affirmed in a set of in vivo studies in mice. 4 These studies demonstrated that silencing of ca9 and ca12 genes using shRNA significantly reduced the rate of xenograft growth and this outcome was attributed to slowed proliferation in the absence of membrane-associated CAs. In humans, studies targeting CA IX-expressing cells using immunotherapy with the monoclonal antibody G250, have reached clinical trials for the treatment of patients with metastatic renal cell carcinoma. 8 Based on the in vivo mouse results using genetic silencing and success with immunotherapy in human cancer patients, the modulation of CA IX and XII with small molecule inhibitors represents a mechanistically novel opportunity with potential for anticancer therapy intervention. From the perspective of targeted cancer therapeutics, this hypothesis has generated scientific interest that so far remains to be comprehensively explored. To date only a few small molecules have been characterized in CA-relevant cell and animal model systems.
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CA inhibitors that incorporate a hydrophilic moiety such as a cationic pyridinium 10, 11 and 'Cp*Ru(II)' salts 12 or carbohydrate moieties [13] [14] [15] [16] [17] have been developed to have limited membrane permeability and so may better target CA IX and XII over CA II.
In order to characterize the potential effect of inhibition of CA IX and XII in tumor hypoxia there is an implied need to develop small molecule, cell impermeable CA inhibitors for use in cell-based models of these extracellular, cancer-linked CAs in tumor hypoxia. Once characterized these molecules should have value as probes to further aid experimental advances in targeted cancer therapies associated with CA and tumor pH homeostasis. 4, 17 Our group's research has focussed on small molecule medicinal chemistry of CA inhibitors, and we recently reported a library of S-glycosides that were potent inhibitors of CA isozymes IX and XII in vitro. 18 Encouraged by the nanomolar activity of these compounds we now elaborate this novel compound class and evaluate for the first time carbohydrate-based CA inhibitors in cell-based models that emulate the role of CA IX in an acidic tumor microenvironment.
Results and Discussion
Compound Design. Sugar-based molecules have proven valuable drug leads, often presenting desirable activity and safety profiles. 19 Many of the sugar-based drugs in clinical use are antiviral, antibacterial or antifungal 20 and benefit from improved solubility, tolerability, stability and/or targeting when compared to non-carbohydrate drugs. Work in our research group has demonstrated the versatility of the Cu(I) catalyzed 1,3-dipolar cycloaddition reaction (1, click chemistry') of organic azides and acetylenes to generate 1,2,3-triazole glycoconjugates. 13 We have developed small molecule membrane impermeable carbohydratebased CA inhibitors from alkynyl sugars and p-azidobenzene sulfonamide, 14, 18 as well as the 'reverse polarity' inhibitors from azido sugars and p-ethynylbenzene sulfonamide. 15 These compounds were designed to selectively target cancer relevant CA isozymes (with an extracellular active site) over other (intracellular) CA isozymes. 13b, 14-16 Compounds comprise a hydrophilic sugar moiety tethered to an aromatic sulfonamide CA pharmacophore through an intervening triazole ring to provide a selection of membrane impermeable small molecule CA inhibitors.
The replacement of the naturally occurring O-glycoside bond by a S-glycoside bond is an approach practiced in the synthesis of carbohydrate containing compounds for downstream biological applications. This isosteric replacement seeks to enhance the stability of the small molecule glycoside towards enzymatic hydrolysis of the glycosidic bond whilst retaining vital molecular recognition interactions with the biological target. 21 We have reported the synthesis and CA enzyme inhibition of S-linked glucose and galactose moieties tethered to a triazoleArSO 2 NH 2 motif, Figure 1a . 18 Our intention here is to build structure-activity relationships (SAR) and structure-property relationships (SPR) around this compound class that can value add to the interpretation of CA inhibitor behaviour in cell-based assays. The target compounds of the present study were thus designed to incorporate a synthetic-handle that would allow further elaboration of the structure to 1,4,5-trisubstituted-1,2,3- 
Chemistry.
Both Meldal 22 and Sharpless 23 discovered that catalytic Cu(I) leads to a dramatic rate enhancement (up to 10 7 -fold) of the 1,3-dipolar cycloaddition reaction (1, of organic azides (R-N 3 ) with alkynes (R′-C≡CH) with exclusive synthesis of the 1,4-disubstituted-1,2,3-triazole product. The reaction is now referred to as the copper-catalyzed azide-alkyne cycloaddition (CuAAC) and has rapidly become the foremost click chemistry reaction. 24, 25 A recent variation to CuAAC involves the combination of a CuI/NBS catalytic system. 26 This variation allows the in situ generation of I + and facilitates the formation of the 5-iodo-1,4-disubstituted 1,2,3-triazole product. We have applied this methodology to sugar alkyne and pazidobenzene sulfonamide substrates, Scheme 1. In our hands this system generates two reaction products in similar yields, these are the 5-iodo- (Figure 1b This click chemistry variant thus gave useful quantities of two products both of which were valuable to the subsequent SAR and SPR investigations of CA inhibition.
We synthesized a set of triazole-based glycoconjugate sulfonamides 5-10 from p-azidobenzene sulfonamide 1 and peracetylated β-S-propynyl glycoside derivatives 2-4 in the presence of CuI and NBS, Scheme 1. Oxidation of the 5-iodo-(5, 7, 9) and 5-H- (6, 8, 10) 
Reagents and conditions. a) peracetylated β-S-propynyl glycoside (2-4, 1.0 equiv.), azide (1, and 28, Scheme 2. This synthetic strategy has provided an additional layer of diversity within this class of CA inhibitor. 4, 2,  compounds 27 and 28.
Scheme 2. Synthesis of target S
Reagents and conditions. CuI (1.0 equiv.), triethylamine (1.0 equiv.), propargyl alcohol (1.0 equiv.) in THF, nitrogen atmosphere, rt, 30 min; then Pd(PPh 3 ) 4 (1.0 equiv. in THF) is added, 50 °C, 30 min.
Carbonic Anhydrase Inhibition. The enzyme inhibition data for 5-28 as well as acetazolamide (AZA) were obtained for the physiologically dominant CA I and II, and tumorassociated CA IX and XII using a stopped flow assay that monitors the physiological reaction (CA catalyzed hydration of CO 2 ), Table 1 PS120-pev cells (lacking CA IX expression) when grown in the neutral media system provide a control cell-based assay that allows us to evaluate the S-glycoside CA inhibitors for generic cytotoxicity. PS120-pca9 cells (overexpressing CA IX) when grown in the acidic media system provide a cell-based assay that allows us to evaluate the impact of S-glycoside CA inhibition on CA IX mediated cell viability. Together these two cell lines provide a cell-based model to study the likely effect of inhibition of CA IX in tumors with small molecules. 4 We focussed arbitrarily on the S-glucoside panel of compounds (5, 6, 11, 12, 17, 18, 21, 22) and the classical CA inhibitor drug AZA to study in the cell-based systems. Our strategy to target the extracellular catalytic domain of cancer-associated CAs is to deliberately manipulate the physicochemical properties of the inhibitor to limit membrane permeability. Compound 5 has a clog P value > 0 (+1.98) and thus is predicted to have some cell membrane permeability, while the cLog P for 17 is < 0 (-0.16) and thus is predicted to be membrane impermeable. Despite their physicochemical difference these compounds were both identified as candidates that target CA IX in the cell models investigated. One explanation for the findings for compound 5 is that its high potency at CA IX (Ki = 6.2 nM) demonstrates that it is a strong binder to CA IX, and even though it is likely to be membrane permeable CA IX may act as an extracellular trap or 'sink' for compound 5 as a consequence of the high binding affinity. In the absence of CA IX over expression compound 5 is likely to enter cells through passive diffusion, however when CA IX is over expressed at the cell surface compound 5 may still bind and have the desired effect. are reported in ppm relative to residual solvent proton (δ = 7.26 ppm). Multiplicity is indicated as follows: s (singlet); d (doublet); t (triplet); m (multiplet); dd (doublet of doublet); ddd (doublet of doublet of doublet); br (broad). Coupling constants are reported in Hertz (Hz).
Conclusions
Melting points are uncorrected. Mass spectra (low and high resolution) were recorded using electrospray as the ionization technique in positive ion negative ion modes as stated. All MS analysis samples were prepared as solutions in methanol. Optical rotations were measured at 25 °C and reported as an average of ten measurements. All compounds were analyzed for purity by HPLC with both UV (200 to 400 nm) and ELSD (Evaporative Light Scattering Detection) detection used. Purity of all compounds was ≥ 95%.
General procedure 1. Synthesis of peracetylated β-S-propynyl glycosides.
To a solution of the per-O-acetylated sugar (1.0 equiv.) in anhydrous CH 3 CN at rt was added thiourea (1.5 equiv.) and boron trifluoride diethyletherate (1.5 equiv.). The resulting mixture was refluxed (~ 1 h), full consumption of the sugar starting material was evidenced by TLC
(1:1 EtOAc/hexane). The reaction mixture was cooled to rt, triethylamine (1. 
p-(4-{[2',3',4',6'-Tetra-O-acetyl-β-D-glucopyranosyl]thiomethyl}-5-iodo-1-H-1,2,3-triazol-

1-yl)benzenesulfonamide (5) and p-(4-{[2',3',4',6'-Tetra-O-acetyl-β-D-glucopyranosyl]thiomethyl}-1-H-1,2,3-triazol-1-
yl)benzenesulfonamide (6)
Title compounds 5 and 6 were prepared from azide 1 and alkyne 2 according to general 81.1 (C-1'); 74.4 (C-5'); 72.9 (C-3'); 69.6 (C-2' or C-4'); 68.1 (C-4' or C-2'); 61.9 (C-6'); 23.2 (SCH 2 ); 20.5, 20.4, 20.3, 20.2 .0 (C-1'); 74.5 (C-5'); 72.9 (C-3'); 69.5 (C-2' or C-4'); 68.0 (C-4' or C-2'); 61.8 (C-6'); 23.2 (SCH 2 ); 20.4, 20.3, 20.3, 20.2 1') ; 73.4 (C-5'); 70.9 (C-3'); 67.5 (C-4'); 67.2 (C-2'); 61.4 (C-6'); 23.5 (SCH 2 ); 20.4, 20.4, 20.3, 20.3 (OCOCH 3 
p-(4-{[2',3',4',6'-Tetra-O-acetyl-β-D-glucopyranosyl]sulfonylmethyl}-5-iodo-1-H-1,2,3-
triazol-1-yl)benzenesulfonamide (11)
The title compound 11 was prepared from compound 5 according to the general procedure 3.
Purification by flash chromatography 
p-(4-{[2',3',4',6'-Tetra-O-acetyl-β-D-glucopyranosyl]sulfonylmethyl}-1-H-1,2,3-triazol-1-
yl)benzenesulfonamide (12)
The title compound 12 was prepared from compound 6 according to the general procedure 3.
triazol-1-yl)benzenesulfonamide (13)
The title compound 13 was prepared from compound 7 according to the general procedure 3. 
yl)benzenesulfonamide (14)
The title compound 14 was prepared from compound 8 according to the general procedure 3.
Purification by flash chromatography ( 
triazol-1-yl)benzenesulfonamide (15)
The title compound 15 was prepared from compound 9 according to the general procedure 3. 73.7 (C-4'); 70.1 (C-2''); 69.6 (C-3''); 68.8 (C-5''); 68.4 (C-4''); 63.1 (C-2'); 63.0 (C-6'); 61.1 (C-6''); 47. 2, 170.0, 169.8, 169.6, 169.5, 169.1, 168.7 (OCOCH 3 ); 144.1, 138.4 (C arom. ); 135.5 (C triazole ); 127.7, 127.7 (CH arom. ); 125.9 (CH triazole ); 120.5, 120.5 (CH arom. ); 95.6 (C-1''); 84.5 (C-1'); 75.5 (C-5'); 74.6 (C-3'); 73.1 (C-4'); 68.9 (C-3''); 68.4 (C-2''); 68.1 (C-5''); 67.8 (C-4''); 66.4 (C-2'); 62.5 (C-6'); 61.5 (C-6''); 47.0 (SO 2 CH 2 ); 20.6, 20.5, 20.4, 20.3, 20.3, 20.2, 20 
p-(4-{(β-D-Glucopyranosyl)thiomethyl}-5-iodo-1-H-1,2,3-triazol-1-yl)benzenesulfonamide (17)
The title compound 17 was prepared from compound 5 according to the general procedure 4.
Lyophilisation afforded the title compound 17 (92% yield) as a highly hygroscopic white solid.
[α] 0, 127.0, 126.6, 126.6 (CH arom. ) ; 84.7 (CI triazole ); 84.3 (C-1'); 80.8 (C-5');
78.2 (C-3'); 73.1 (C-4'); 69.9 (C-2'); 61.1 (C-6'); 23. 
p-(4-{(β-D-Glucopyranosyl)thiomethyl}-1-H-1,2,3-triazol-1-yl)benzenesulfonamide (18)
The title compound 18 was prepared from compound 6 according to the general procedure 4.
Lyophilisation afforded the title compound 18 (97% yield) as a highly hygroscopic white solid.
[α] 
yl)benzenesulfonamide (19)
The title compound 19 was prepared from compound 7 according to the general procedure 4.
Lyophilisation afforded the title compound 19 (91% yield) as a highly hygroscopic white solid.
[α] 1, 127.1, 126.7, 126.7 (CH arom. ); 85.0 (CI triazole ); 84.8 (C-1'); 79.1 (C-5'); 74.8 (C-3'); 70.0 (C-4'); 68.3 (C-2'); 60.4 (C- The title compound 20 was prepared from compound 8 according to the general procedure 4.
Lyophilisation afforded the title compound 20 (96% yield) as a highly hygroscopic white solid.
yl)benzenesulfonamide (21)
The title compound 21 was prepared from compound 11 according to the general procedure 4.
Lyophilisation afforded the title compound 21 (93% yield) as a highly hygroscopic white solid.
[α] The title compound 22 was prepared from compound 12 according to the general procedure 4.
Lyophilisation afforded the title compound 22 (93% yield) as a highly hygroscopic white solid.
yl)benzenesulfonamide (23)
The title compound 23 was prepared from compound 13 according to the general rocedure 4.
Lyophilisation afforded the title compound 23 (86% yield) as a highly hygroscopic white solid.
[α] The title compound 24 was prepared from compound 14 according to the general procedure 4.
Lyophilisation afforded the title compound 24 (86% yield) as a highly hygroscopic white solid.
[α] The title compound 25 was prepared from compound 15 according to the general procedure 4.
Lyophilisation afforded the title compound 25 (72% yield) as a highly hygroscopic white solid.
[α] The title compound 26 was prepared from compound 16 according to the general procedure 4.
Lyophilisation afforded the title compound 26 (76% yield) as a highly hygroscopic white solid.
[α] 20.4, 20.4, 20.4, 20.3 (OCOCH 3 (SCH 2 ); 20.5, 20.5, 20.4, 20.4 (OCOCH 3 Carbonic anhydrase catalytic inhibition assay. An SX.18MV-R Applied Photophysics stopped-flow instrument has been used for assaying the CA I, II, IX and XII CO 2 hydration activity. 29 Phenol red (at a concentration of 0.2 mM) has been used as indicator, working at the absorbance maximum of 557 nm, with 10 mM Hepes (pH 7.5) as buffer, 0.1 M NaClO 4 (for maintaining constant the ionic strength -this anion is not inhibitory), following the CAcatalyzed CO 2 hydration reaction for a period of 10 -100 s. Saturated CO 2 solutions in water at 20 ºC were used as substrate. Stock solutions of inhibitors were prepared at a concentration of 10 -50 mM (in the assay buffer) and dilutions up to 1 nM done with the assay buffer mentioned above. Inhibitor and enzyme solutions were preincubated together for 15 min at room temperature prior to assay, in order to allow for the formation of the E-I complex. The inhibition constants were obtained by non-linear least-squares methods using PRISM 3. The curve-fitting algorithm allowed us to obtain the IC 50 values, working at the lowest concentration of substrate of 1.7 mM), from which K i values were calculated by using the Cheng-Prusoff equation. The catalytic activity (in the absence of inhibitors) of these enzymes was calculated from Lineweaver-Burk plots and represent the mean from at least three different determinations. Enzyme concentrations were 10.3 nM for CA I and CA II, 12 nM for CA IX and 15 nM for hCA XII. Enzymes used here were recombinant ones.
Cell Culture and Hypoxic Exposure.
Chinese hamster lung CCL39 fibroblasts (American Type Culture Collection) and the CCL39-derived mutant PS120 cells, lacking the amiloride-sensitive Na + /H + exchanger, 31 were maintained in DMEM (Sigma) supplemented with 7.5% FCS in a humidified atmosphere of 5% CO 2 , 95% air, or 100% air at 37 °C. The colon adenocarcinoma cell lines LS174Tr, expressing the tetracycline (Tet) repressor were maintained in DMEM supplemented with 10%
FCS and blasticidin (10 µg/ml, Invitrogen). The incubation in hypoxia at 1% O 2 was carried out at 37 °C in 95% humidity and 5% CO 2 /94% N 2 in a sealed anaerobic workstation (Ruskinn).
Stable Transgenic Cells.
PS120 cells were transfected with the pca9 vector as previously described. 4 LS174Tr cells were transfected with Tet (10 µg/ml)-inducible short hairpin RNA targeting ca9 (shca9) and transduced with lentiviral particles containing nontarget shRNA (ctl) and shRNA-ca12 (ca12 -) to constitutively silence ca12, as previously described. 4 These cells are named, respectively,
